23rd Annual Meeting & Exposition, September 23 – 26, 2026 – Scottish Events Campus, Glasgow, Scotland

The 23rd Annual Meeting of the International Myeloma Society convenes September 23 through 26 at the Scottish Event Campus in Glasgow, and the society’s own preview frames the gathering around a question the field could not seriously ask a decade ago: how cure should be defined, measured and extended to more patients.

In a news release issued August 26, IMS said more than 3,000 researchers and clinicians from over 75 countries will examine research drawn from more than 635 abstracts and 35 late-breaking presentations.

The program committee singled out several presentations. One is a large sustained-MRD analysis that attempts to identify an ultra-low-risk group, defined by durable MRD negativity, genomic risk and disease stage, whose outcomes after stopping therapy are strong enough to support a data-driven framework for who may be cured.

Another is first-in-human proof of concept for IASO206, a BCMA-directed CAR-T generated inside the body from a single intravenous infusion, without leukapheresis, external manufacturing or lymphodepletion. BMS-986453, a dual-targeting BCMA and GPRC5D CAR-T built to counter antigen loss, will report first-in-human results in heavily pretreated patients, and IBI3003, a GPRC5D by BCMA by CD3 trispecific antibody, will present durable responses in high-risk relapsed disease.

Fixed-duration cevostamab from CAMMA 1, a 48-month BENEFIT analysis of isatuximab plus VRd in transplant-ineligible patients, and a French trial of daratumumab-VRd with tandem transplant in primary plasma cell leukemia round out the list.

Four thematic sessions anchor the meeting: newly diagnosed disease, how to treat first relapse, blood-based technology for diagnosis and monitoring, and monitoring the immune system while preventing infections and adverse effects.

Joint sessions with AACR on the microbiome’s role in CAR-T response and with EHA on genomics and the responsible use of AI are scheduled, along with an expert debate on choosing among CAR-T, T-cell engagers and antibody-drug conjugates. IMS President Philippe Moreau, MD, described a field being redrawn in real time, with immunotherapies once reserved for late lines moving toward the front and cell therapies now generated inside the patient.

Awards will go to Sagar Lonial, MD, of Emory’s Winship Cancer Institute, who receives the Waldenström Lifetime Achievement Award; Sonja Zweegman, MD, PhD, who receives the Bart Barlogie Clinical Investigator Award; and Nizar Bahlis, MD, who receives the Ken Anderson Basic and Translational Research Award.

Reference
International Myeloma Society. International Myeloma Society (IMS) Spotlights Breakthrough Science at 2026 Annual Meeting. News release. August 26, 2026. https://www.myelomasociety.org/ims-news-room/international-myeloma-society-ims-spotlights-breakthrough-science-at-2026-annual-meeting/